Levodopa with carbidopa diminishes glycogen concentration, glycogen synthase activity, and insulin-stimulated glucose transport in rat skeletal muscle

Journal of Applied Physiology

Volumn 97, Issue 6, 2004, Pages 2339-2346

  Smith, Jill L ^a   Ju, Jeong Sun ^a   Saha, Bithika M ^a   Racette, Brad A ^b,c   Fisher, Jonathan S ^a  

^a SAINT LOUIS UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c American Parkinson Disease Association Advanced Center for Parkinson Research   (United States)

Author keywords

Diabetes; Dopamine; Insulin resistance; Parkinson's disease

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBIDOPA PLUS LEVODOPA; CYCLIC AMP; GLUCOSE; GLYCOGEN; GLYCOGEN SYNTHASE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; PROPRANOLOL; PROTEIN KINASE B;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GLUCOSE TRANSPORT; HUMAN; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN RESPONSE; LONG TERM CARE; MALE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SINGLE DRUG DOSE; SKELETAL MUSCLE;

ANIMALS; CARBIDOPA; DOPAMINE AGENTS; DRUG SYNERGISM; GLUCOSE; GLUCOSE TOLERANCE TEST; GLYCOGEN; GLYCOGEN SYNTHASE; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LEVODOPA; MALE; MUSCLE, SKELETAL; RATS; RATS, WISTAR;

EID: 9244255817     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/japplphysiol.01219.2003     Document Type: Article

References (43)

1. Bae SS, Cho H, Mu J, and Birnbaum MJ. Isoform-specific regulation of insulin-dependent glucose uptake by Akt/protein kinase B. J Biol Chem 278: 49530-49536, 2003.
2. Barbeau A, Giguere R, and Hardy J. Experience clinique avec le tolbutamide dans la maladie de parkinson. Union Med Can 90: 147-151, 1961.
3. Boyd AE III, Lebovitz HE, and Feldman JM. Endocrine function and glucose metabolism in patients with Parkinson's disease and their alternation by L-Dopa. J Clin Endocrinol Metab 33: 829-837, 1971.
4. Brandabur M. Current therapy in Parkinson's disease. Surg Neurol 52: 318-322, 1999.
5. Brion N, Kollenbach K, Marion MH, Gregoire A, Advenier C, and Pays M. Effect of macrolide (spiramycin) on the pharmacokinetics of L-Dopa and carbidopa in healthy volunteers. Clin Neuropharmacol 15: 229-235, 1992.
6. Brooks DJ. Dopamine agonists: their role in the treatment of parkinson's disease. J Neurol Neurosurg Psychiatry 68: 685-689, 2000.
7. Cohen P and Hardie DG. The actions of cyclic AMP on biosynthetic processes are mediated indirectly by cyclic AMP-dependent protein kinase. Biochim Biophys Acta 1094: 292-299, 1991.
8. Cross DA, Alessi DR, Cohen P, Andjelkovich M, and Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785-789, 1995.
9. Deleu D, Sarre S, Ebinger G, and MichYotte. The effect of carbidopa and entacapone pretreatment on the L-dopa pharmacokinetics and metabolism in blood plasma and skeletal muscle in beagle dog: an in vivo microdialysis study. J Pharmacol Exp Ther 273: 1323-1331, 1995.
10. Dent P, Lavoinne A, Nakielny S, Caudwell FB, Watt P, and Cohen P. The molecular mechanism by which insulin stimulates glycogen synthesis in mammalian skeletal muscle. Nature 348: 302-308, 1990.
11. Eldrup E, Richter EA, and Christensen NJ. DOPA, norepinephrine, and dopamine in rat tissues: no effect of sympathectomy on muscle DOPA. Am J Physiol Endocrinol Metab 256: E284-E287, 1989.
12. Esposito DL, Li Y, Cama A, and Quon MJ. Tyr(612) and Tyr(632) in human insulin receptor substrate-1 are important for full activation of insulin-stimulated phosphatidylinositol 3-kinase activity and translocation of GLUT4 in adipose cells. Endocrinology 142: 2833-2840, 2001.
13. Fell RD, McLane JA, Winder WW, and Holloszy JO. Preferential resynthesis of muscle glycogen in fasting rats after exhausting exercise. Am J Physiol Regul Integr Comp Physiol 238: R328-R332, 1980.
14. Fisher JS, Nolte LA, Kawanaka K, Han DH, Jones TE, and Holloszy JO. Glucose transport rate and glycogen synthase activity both limit skeletal muscle glycogen accumulation. Am J Physiol Endocrinol Metab 282: E1214-E1221, 2002.
15. Foianini KR, Steen MS, Kinnick TR, Schmit MB, Youngblood EB, and Henriksen EJ. Effects of exercise training and ACE inhibition on insulin action in rat skeletal muscle. J Appl Physiol 89: 687-694, 2000.
16. Gosmanov AR, Wong JA, and Thomason DB. Duality of G protein-coupled mechanisms for beta-adrenergic activation of NKCC activity in skeletal muscle. Am J Physiol Cell Physiol 283: C1025-C1032, 2002.
17. Hakanson R, Lundquist I, and Rerup C. On the hyperglycaemic effect of dopa and dopamine. Eur J Pharmacol 1: 114-119, 1967.
18. Hirai K and Gondo K. über Dopa-Hyperglykämie. Biochem Z 189: 92-100, 1927.
19. Hojlund K, Staehr P, Hansen BF, Green KA, Hardie DG, Richter EA, Beck-Nielsen H, and Wojtaszewski JF. Increased phosphorylation of skeletal muscle glycogen synthase at NH(2)-terminal sites during physiological hyperinsulinemia in type 2 diabetes. Diabetes 52: 1393-1402, 2003.
20. Hunt DG, Ding Z, and Ivy JL. Clenbuterol prevents epinephrine from antagonizing insulin-stimulated muscle glucose uptake. J Appl Physiol 92: 1285-1292, 2001.
21. Iozzo P, Pratipanawatr T, Pijl H, Vogt C, Kumar V, Pipek R, Matsuda M, Mandarine LJ, Cusi KJ, and DeFronzo RA. Physiological hyperinsulinemia impairs insulin-stimulated glycogen synthase activity and glycogen synthesis. Am J Physiol Endocrinol Metab 280: E712-E719, 2001.
22. Jue T, Rothman DL, Shulman GI, Tavitian BA, DeFronzo RA, and Shulman RG. Direct observation of glycogen synthesis in human muscle with 13C NMR. Proc Natl Acad Sci USA 86: 4489-4491, 1989.
23. Kim S, Jee K, Kim D, Koh H, and Chung J. Cyclic AMP inhibits Akt activity by blocking the membrane localization of PDK1. J Biol Chem 276: 12864-12870, 2003.
24. Laurent D, Hundal RS, Dresner A, Price TB, Vogel SM, Petersen KF, and Shulman GI. Mechanism of muscle glycogen autoregulation in humans. Am J Physiol Endocrinol Metab 278: E663-E668, 2000.
25. Lawrence JC Jr and Roach PJ. New insights into the role and mechanism of glycogen synthase activation by insulin. Diabetes 46: 541-547, 1997.
26. Lee AD, Hansen PA, Schluter J, Gulve EA, Gao J, and Holloszy JO. Effects of epinephrine on insulin-stimulated glucose uptake and GLUT-4 phosphorylation in muscle. Am J Physiol Cell Physiol 273: C1082-C1087, 1997.
27. Lipman IJ, Boykin ME, and Flora RE. Glucose intolerance in Parkinson's disease. J Chron Dis 27: 573-579, 1974.
28. Nakielny S, Campbell DG, and Cohen P. The molecular mechanism by which adrenalin inhibits glycogen synthesis. Eur J Biochem 199: 713-722, 1991.
29. Passoneau JV and Lowry OH. Enzymatic Analysis: A Practical Guide. Totowa, NJ: Humana, 1993.
30. Rose S, Jenner P, and Marsden CD. The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats. Mov Disord 3: 117-125, 1988.
31. Schubert D, Tarikas H, and LaCorbiere M. Neurotransmitter regulation of adenosine 3′,5′-monophosphate in clonal nerve, glia, and muscle cell lines. Science 102: 471-472, 1976.
32. Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA, and Shulman RG. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med 322: 223-228, 1990.
33. Sirtori CR, Bolme P, and Azarnoff DL. Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism. N Engl J Med 287: 729-733, 1972.
34. Sugiyama A, Wiegn P, McKnite S, and Lurie KG. Enzymatic fluorometric assay for tissue cAMP. J Clin Lab Anal 8: 437-442, 1994.
35. Summers SA, Yin VP, Whiteman EL, Garza LA, Cho H, Tuttle RL, and Birnbaum MJ. Signaling pathways mediating insulin-stimulated glucose transport. Ann NY Acad Sci 892: 169-186, 1999.
36. Suzuki Y, Lanner C, Kim JH, Vilardo PG, Zhang H, Yang J, Cooper LD, Steele M, Kennedy A, Bock CB, Scrimgeour A, Lawrence JC Jr, and DePaoli-Roach AA. Insulin control of glycogen metabolism in knockout mice lacking the muscle-specific protein phosphatase PP1G/RGL. Mol Cell Biol 21: 2683-2694, 2001.
37. Thompson Healthcare. Physicians' Desk Reference. Montvale, NJ: Thompson PDR, 2003.
38. Thong FS, Derave W, Kiens B, Graham TE, Urso B, Wojtaszewski JF, Hansen BF, and Richter EA. Caffeine-induced impairment of insulin action but not insulin signaling in human skeletal muscle is reduced by exercise. Diabetes 51: 583-590, 2002.
39. Tuite P and Ebbitt B. Dopamine agonists. Semin Neurol 21: 9-14, 2000.
40. Vanhaesebroeck B and Alessi DR. The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 346: 561-576, 2000.
41. Wang L, Wang X, and Proud CG. Activation of mRNA translation in cardiac myocytes by insulin involves multiple rapamycin-sensitive steps. Am J Physiol Heart Circ Physiol 278: H1056-H1068, 2000.
42. Young DA, Wallberg-Henriksson H, Cranshaw J, Chen M, and Holloszy JO. Effect of catecholamines on glucose uptake and glycogenolysis in rat skeletal muscle. Am J Physiol Cell Physiol 248: C406-C409, 1985.
43. Yu S, Castle A, Chen M, Lee R, Takeda K, and Weinstein LS. Increased insulin sensitivity in Gsα knockout mice. J Biol Chem 276: 19994-19998, 2001.